DynAML
Financiado
Elucidating the Spatial and Temporal Dynamics of Acute Myeloid Leukemia Progress...
Elucidating the Spatial and Temporal Dynamics of Acute Myeloid Leukemia Progression Using Functional Omics and High-Throughput In Vivo Screening
Advances in sequencing-based phylogenetic studies applied to cancer evolution have led to the observation that the linear accumulation of oncogenic alterations over individuals’ lifespan does not match the late life pattern of can...
Advances in sequencing-based phylogenetic studies applied to cancer evolution have led to the observation that the linear accumulation of oncogenic alterations over individuals’ lifespan does not match the late life pattern of cancer incidence. It has thus become clear that beyond the sequential accumulation of oncogenic driver mutations, additional factors also support cancer outgrowth. The temporal and spatial dynamics of tumor evolution represent two of the most critical mutation-independent variables to consider. Hence, we hypothesized that the dual features of aging and spatial dissemination promote critical fitness gains that are at least as significant as driver mutations in cancer. The goal of this proposal is to investigate the spatial and temporal determinants of tumor progression and to dissect the contributions of these processes to cancer pathogenicity.
Due to its quite unique occurrence pattern and propagation characteristics, Acute Myeloid Leukemia (AML) is the prototypical disease model that we have elected to template such spatiotemporal-dependent features of disease development. To study these features, we engineered two mouse models of leukemia dissemination and aging using serially-transplantable MLL-AF9-driven leukemic blasts. Using these two models, we propose to i) combine metabolomic- and epigenomic-based profiling to portray the spatiotemporal dynamics of leukemia growth; ii) deploy single-cell transcriptomics coupled with lineage tracing experiments to reveal the pre-deterministic attributes of such dynamics; and iii) leverage innovative multimodal in vivo shRNA and CRISPRa screening approaches to pinpoint and functionally characterize the critical age- and dissemination-related effector genes involved in leukemic progression. The comprehensive analysis of their unknown function will potentially define new therapeutic routes in AML, and, given the holistic nature of the spatiotemporal characteristics studied, in other cancers as well.
ver más
Duración del proyecto: 68 meses
Fecha Inicio: 2023-06-13
Fecha Fin: 2029-02-28
Fecha Fin: 2029-02-28
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-06-13
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2022-COG:
ERC CONSOLIDATOR GRANTS
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5